Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Patterson

Showing results (1091-1100 of 1,160) with videos related to

Pageof 116
Sort By:
Seminars in Hematology|May 29, 2025
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk diseasePrashant Kapoor, Meletios A Dimopoulos, Stephen M Ansell, et al.
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Investigative Ophthalmology & Visual Science|December 13, 2024
Changes in Waveguiding Cone Photoreceptors and Color Vision in Patients With Diabetes MellitusMegan Vaughan, Nicole Tay, Angelos Kalitzeos, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Intensive Care Medicine|June 30, 2018
Increasing evidence-based interventions in patients with acute infections in a resource-limited setting: a before-and-after feasibility trial in Gitwe, RwandaOlivier Urayeneza, Pierre Mujyarugamba, Zacharie Rukemba, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Pageof 116

Showing results (1091-1100 of 1,160) with videos related to

Sort By:
Pageof 116
Seminars in Hematology|May 29, 2025
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk diseasePrashant Kapoor, Meletios A Dimopoulos, Stephen M Ansell, et al.
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Investigative Ophthalmology & Visual Science|December 13, 2024
Changes in Waveguiding Cone Photoreceptors and Color Vision in Patients With Diabetes MellitusMegan Vaughan, Nicole Tay, Angelos Kalitzeos, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Intensive Care Medicine|June 30, 2018
Increasing evidence-based interventions in patients with acute infections in a resource-limited setting: a before-and-after feasibility trial in Gitwe, RwandaOlivier Urayeneza, Pierre Mujyarugamba, Zacharie Rukemba, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Journal of Medicinal Chemistry|March 4, 1998
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacyD J Kempf, H L Sham, K C Marsh, et al.
Pageof 116